Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD).
Embrace Technology Innovations to Optimise LNP Formulation, Alternative LNP Raw Materials, Process Control to Achieve Seamless Scale-Up, Compliance & Cos